CCCC
C4 Therapeutics, Inc.
Next earnings Aug 5, 2026 · consensus $-0.23 EPS, $4.08M rev
Last earnings +0.0% on 2026-05-12
$4.26
▼ -3.18%$4.26▲ +189.80%
over 1Y
L $1.40EODHDH $4.40
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today-3.2%
1W+3.4%
1M+13.9%
3M+76.8%
YTD+120.7%
1Y+189.8%
Sell
Conviction
Horizon
Medium (3–12mo)
Street · 14 analysts
Buy
Conservative balance sheet (liabilities/equity 0.40x); but unprofitable (net margin -292.1%).
Revenue (FY2025) $35.9M · FY2025
C4 Therapeutics, Inc. shows $35.9M in FY2025 revenue (+1.0% YoY), a -292.1% net margin, and -40.9% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $45.8M | $31.1M | $20.8M | $35.6M | $35.9M |
| Gross profit | — | — | — | — | — |
| Operating income | -$82.1M | -$130M | -$139M | -$120M | -$115M |
| Net income | -$83.9M | -$128M | -$132M | -$105M | -$105M |
| Diluted EPS | -$1.82 | -$2.62 | -$2.67 | -$1.52 | -$1.27 |
| Net margin | -183.2% | -412.2% | -638.3% | -296.0% | -292.1% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$341M
EV / EBITDA—
EV / Sales9.5
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-25.3%
FCF yield-23.9%
Quality & risk
ROIC (est.)-35.5%
Free cash flow-$99.3M
Total debt$0.00
Net cash$74.6M
Altman Z-Score-0.65 distress
Piotroski F-Score4/8
Capital returns
Buyback yield0.0%
Dividend yield (est.)—
Shareholder yield0.0%
Shares Δ YoY+37.5%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
Recent filings
all on EDGAR ↗4Period ending 2026-06-242026-06-26open ↗4Period ending 2026-06-242026-06-26open ↗4Period ending 2026-06-242026-06-26open ↗4Period ending 2026-06-242026-06-26open ↗4Period ending 2026-06-242026-06-26open ↗4Period ending 2026-06-242026-06-26open ↗4Period ending 2026-06-242026-06-26open ↗4Period ending 2026-06-242026-06-26open ↗8-KPeriod ending 2026-06-242026-06-24open ↗8-KPeriod ending 2026-06-112026-06-11open ↗4Period ending 2026-06-012026-06-04open ↗144Filing2026-05-28open ↗
Frequently asked
- Is C4 Therapeutics, Inc. (CCCC) a buy?
- CCCC currently carries a Sell rating with 3/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity 0.40x); but unprofitable (net margin -292.1%).
- What is C4 Therapeutics, Inc.'s quality score?
- CCCC scores 42.686274509803916/100 (grade D) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001662579, latest 10-Q filed 2026-05-12) · EODHD · as of 6/26/2026, 5:59:26 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.